Cell line · CVCL_1289
Papers46
1 to 20 of 46
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Genome-wide CRISPR screen identifies AMBRA1 as a potential biomarker of response to platinum-based therapies in oral squamous cell carcinomas. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Matrix Stiffness Drives Aggressive Phenotype in Tongue Squamous Cell Carcinoma via Mechanotransduction-Stromal Signalling. | Int Dent J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LMO4 promotes OSCC progression by inducing RAB17 degradation and ferroptosis resistance. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| In vitro assessment of BBI608 in 2D and 3D culture models for drug repositioning in oral squamous cell carcinoma. | Oncol Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| EGFRvIII-driven microenvironmental fibroblast activation and transformation accelerate oral cancer progression via lipocalin-2/STAT3 axis. | Neoplasia | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The PTTG1/VASP axis promotes oral squamous cell carcinoma metastasis by modulating focal adhesion and actin filaments. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting ferroptosis for improved radiotherapy outcomes in HPV-negative head and neck squamous cell carcinoma. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| TNO155 is a selective SHP2 inhibitor to target PTPN11-dependent oral squamous cell carcinoma. | Heliyon | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Development and Characterization of a Three-Dimensional Organotypic In Vitro Oral Cancer Model with Four Co-Cultured Cell Types, Including Patient-Derived Cancer-Associated Fibroblasts. | Biomedicines | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC. | Front Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Betaine Induces Apoptosis and Inhibits Invasion in OSCC Cell Lines. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Circular RNA from Tyrosylprotein Sulfotransferase 2 Gene Inhibits Cisplatin Sensitivity in Head and Neck Squamous Cell Carcinoma by Sponging miR-770-5p and Interacting with Nucleolin. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Biological and genetic characterization of a newly established human external auditory canal carcinoma cell line, SCEACono2. | Sci Rep | 2023 | Cellosaurus cites it | PubMed | |
| Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Crosstalk between oral squamous cell carcinoma cells and cancer-associated fibroblasts via the TGF-β/SOX9 axis in cancer progression. | Transl Oncol | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway. | Elife | 2020 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1289/papers